- Home
- GRVY vs BNR Comparison
GRVY vs BNR Comparison
Compare GRVY & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GRVY | BNR |
|---|---|---|
| Founded | 2000 | 2014 |
| Country | South Korea | China |
| Employees | N/A | N/A |
| Industry | Business Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 399.1M | 322.1M |
| IPO Year | 2005 | 2019 |
Fundamental Metrics
Financial Performance| Metric | GRVY | BNR |
|---|---|---|
| Price | $62.45 | $22.64 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 17.5K | 11.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $136.32 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $53.12 | $2.18 |
| 52 Week High | $74.75 | $41.72 |
Technical Indicators
Market Signals| Indicator | GRVY | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 41.83 | 37.34 |
| Support Level | $62.10 | $19.10 |
| Resistance Level | $65.27 | $24.23 |
| Average True Range (ATR) | 2.40 | 2.00 |
| MACD | -0.54 | -0.83 |
| Stochastic Oscillator | 6.20 | 17.49 |
Price Performance
Historical ComparisonAbout GRVY GRAVITY Co. Ltd. American Depository Shares
GRAVITY Co Ltd is an online and mobile games developer and publisher based in Korea. Its principal product, Ragnarok Online, is an online game which is available in more than 91 markets. Its games include Ragnarok Online, Requiem, Dragonica (Dragon Saga), Ragnarok Online II, Requiem Online, and R.O.S.E. Online. The company generates revenue from online games, mobile games and other sources including character based merchandise and animation.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.